Magnitude and associated factors of contrast induced nephropathy among patients undergoing coronary angiography and interventions at a cardiac referral hospital in Tanzania - a cross-sectional study

Pilly Chillo, Ng’wigulu Malaja, Peter Kisenge

Corresponding author: Pilly Chillo, Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. pchillo2000@gmail.com

Received: 24 Jun 2020 - Accepted: 16 Mar 2021 - Published: 29 Mar 2021

Keywords: Contrast induced nephropathy, acute kidney injury, Tanzania, sub-Saharan Africa

Copyright: Pilly Chillo et al. Pan African Medical Journal (ISSN: 1937-8688). This is an Open Access article distributed under the terms of the Creative Commons Attribution International 4.0 License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cite this article: Pilly Chillo et al. Magnitude and associated factors of contrast induced nephropathy among patients undergoing coronary angiography and interventions at a cardiac referral hospital in Tanzania - a cross-sectional study. Pan African Medical Journal. 2021;38(311). 10.11604/pamj.2021.38.311.24536

Available online at: https://www.panafrican-med-journal.com/content/article/38/311/full

Magnitude and associated factors of contrast induced nephropathy among patients undergoing coronary angiography and interventions at a cardiac referral hospital in Tanzania - a cross-sectional study

Pilly Chillo¹², Ng’wigulu Malaja³, Peter Kisenge²

¹Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania, ²Department of Cardiology, Jakaya Kikwete Cardiac Institute, Dar es Salaam, Tanzania

*Corresponding author
Pilly Chillo, Department of Internal Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
Abstract

Introduction: contrast media are increasingly used in diagnostic and interventional procedures but are also known causes of acute kidney injury - a condition known as contrast induced nephropathy (CIN). We aimed to determine the magnitude and associated factors of CIN among patients undergoing coronary angiography and percutaneous coronary intervention at a cardiac referral hospital in Tanzania. Methods: all adult patients undergoing elective coronary angiography and percutaneous coronary intervention at Jakaya Kikwete Cardiac Institute were consecutively enrolled between August 2017 and January 2018, if they fulfilled the inclusion criteria. Pre-procedure, 24- and 72-hours' post procedure serum creatinine was measured. CIN was defined as increase of ≥25% or absolute increase of ≥44μmol/L of serum creatinine within 72 hours following exposure to contrast media. Data analysis were done using SPSS Version 20. P-value of <0.05 was considered statistically significant. Results: in total, 210 (94.6%) out of 222 patients seen during the study period fulfilled the inclusion criteria and were enrolled. Their mean (SD) age was 61.3 (10.9) years and 64.3% were men. Hypertension, diabetes, smoking and alcohol consumption was present in 86.7%, 37.7%, 12.4% and 37.6% respectively. The incidence of CIN was 19% within 72 hours post procedure. On multivariate logistic regression analysis, independent factors for developing CIN were history of heart failure (aOR=7.34), central obesity (aOR=3.12), triple vessel disease (aOR=10.14) and post procedure stay of ≥3 days (aOR=4.1), all p<0.05. Conclusion: the incidence of CIN found in this population is high (19%) and is associated with heart failure, obesity, multi-vessel disease and longer post-procedure hospital stay.

Introduction

The growing use of imaging and interventional procedures that involve the administration of intravascular contrast media in sub-Saharan Africa [1] will significantly increase the number of patients at risk to develop contrast induced nephropathy (CIN). CIN is defined as the impairment of renal function, measured as either a 25% increase in serum creatinine from baseline or 44 μmol/L increase in absolute serum creatinine within 72 hours of intravenous contrast administration [2]. In large observational studies conducted in North America, CIN has been established as the third most common cause of hospital-acquired acute kidney injury, after impaired renal perfusion and use of nephrotoxic medications [3,4]. The frequency of occurrence of CIN differs depending on the procedure performed as well as the studied population. Coronary angiography and percutaneous coronary interventions have been associated with highest rates of CIN, reported to occur in 11 - 16% among unselected cardiac patients [5] and as high as 50% among sub-groups of cardiac patients with high-risk [6].

Despite an increase in the use of contrast media, CIN has been largely understudied in sub-Saharan Africa, with only a few studies reported from South Africa, Kenya and Nigeria [7-9] while in Tanzania no documented literature exist regarding CIN. The previous studies from the region reported an incidence of CIN ranging from 9.9% to 35.9% [7-9] with most of the patients being exposed to contrast media following radiological investigation of contrast enhanced computed tomography. In the study by Banda et al. from South Africa, presence of CIN was associated with longer hospital stay and mortality at 3 months, indicating adverse effects of CIN among native sub-Saharan Africans [7]. With regards to risk factors associated with the development of CIN, several studies have documented clinical factors including pre-existent chronic kidney disease, diabetes mellitus, advanced age, anemia, heart failure, metabolic syndrome, hypoalbuminemia and dehydration, as well as factors related to the procedure performed and the contrast medium used [10]. However, reports have been inconsistent in risk factors for CIN [11] and more need to be done to generate local data.
In Tanzania, as it is for many sub-Saharan African countries coronary artery diseases has been increasing [12] and in 2016 alone the Jakaya Kikwete Cardiac Institute (JKCI) performed coronary angiography and/or interventions in 620 patients and the numbers are increasing. It is therefore likely that CIN will pose a significant challenge both for cardiologists and nephrologists. This study was carried out to document the magnitude and associated factors of CIN among patients undergoing percutaneous coronary angiography and interventions at the Institute, in order to obtain local baseline data to inform preventive measures.

Methods

Study area, population and period: the study was carried out at JKCI, which is the national referral hospital for cardiac conditions. The hospital has a bed capacity of 104 and an average of 5 patients undergoing coronary angiography or intervention daily. All adult patients (≥18 years) who underwent elective coronary angiography and/or percutaneous coronary intervention at JKCI during the study period were invited to participate. Patients on dialysis and those who did not give consent to participate were excluded. The study was conducted between August 2017 and January 2018.

Study design and sample size: this was an observational, hospital-based cross section study. Patients were consecutively enrolled in the study until a pre-defined sample size of 210 patients was reached, which was sufficient to estimate the prevalence of CIN at 5% error margin and power of 80%, considering the previous known prevalence of CIN in South Africa [7].

Data collection procedure

Questionnaire and data collection forms: a structured questionnaire was used to collect patients’ information, which included socio-demographic characteristics (age, sex, marital status etc), cardiovascular disease history, drug history, pre-existing renal disease and history of previous exposure to contrast medium. Patients’ hospital case notes were used to determine other co-morbidities, as well as pre-procedure laboratory results of the patient. Information from patients’ notes was recorded into pre-coded data collection forms.

Physical examination, anthropometric and blood pressure measurements: patients’ height and weight was examined and recorded. Height was measured by use of a stadiometer with patients wearing no shoes and recorded to the nearest centimeter. Weight was measured by using pneumatic weighing machine (Mormet®, China) and recorded to the nearest 0.5 kg. Height and weight were used to calculate body mass index (BMI). Obesity was defined as BMI ≥30 kg/m². Waist circumference was measured by use of a tape measure and recorded to the nearest centimeter. Central obesity was defined as waist circumference >88 cm for females and >102 cm for males [13]. Blood pressure was taken using an automated BP machine. Measurements were taken pre-procedure, intra-, at 24hr- and 72hr-post procedure. Hypertension was defined as pre-procedure BP of ≥140/90 mmHg or known hypertensive on medications.

Laboratory investigations and definition of CIN: serum creatinine was measured within 24 hours before the procedure and at 24- and 72-hours post procedure. CIN was defined as an absolute increase of serum creatinine of 44 μmol/l or a 25% increase from pre-procedural serum creatinine level [2]. Serum creatinine levels were used to calculate the estimated glomerular filtration rate (eGFR) using the modification of diet in renal disease (MDRD) Study equation [14] and patients were categorized into different stages of chronic kidney disease (CKD) as per guidelines [15]. Patient’s hemoglobin level, serum cholesterol and fasting blood glucose were done within 24 hours before the procedure. All tests were done at the Muhimbili National Hospital Central Pathology Laboratory which is the reference laboratory for Tanzania.
Data processing and analysis: data entry and analysis were done using Statistical Package for Social Sciences (SPSS) Version 20.0 software. Data is expressed as mean (SD) for continuous variables and as number (%) for categorical variables. Groups of patients were compared using Chi-square test or Fisher’s exact test for categorical variables and unpaired students’ t-test for continuous variables. Multivariate logistic regression analysis was performed to determine independent factors associated with CIN among study patients. A two tailed p-value of less than 0.05 was considered to indicate a statistically significant difference.

Ethical issues: ethical clearance was obtained from the Research and Publications Committee of Muhimbili University of Health and Allied Sciences. All patients had to sign an informed consent form before any data were collected. Patients were free to choose to be part of the study, refusal of which did not interfere with their right to get service at the hospital.

Results

Socio-demographic and clinical characteristics of the study population: during the study period, 222 patients fulfilled the inclusion criteria and were enrolled but only 210 had a second blood sample for creatinine analysis post procedure. Among the 12 patients without second creatinine results; 2 died before the second creatinine sample was collected, 5 had lost creatinine results and 5 did not come for the second creatinine measurements.

Patients’ characteristics are summarized in Table 1. Of the 210 patients analyzed, 135 (64.3%) were men. The mean (SD) age of the total population was 61.3 (10.9) years (range 33 - 86 years) and most of the patients were in the age group 41 - 65 years. Hypertension was the most prevalent cardiovascular risk factor, being present in 86.7% of the total population. Previous history of heart failure and of renal failure was present in 3.8% and 8.6% respectively, while history of previous coronary angiography procedure was present in 22.6% of the patients. Majority of the study patients had good renal function pre-procedure. None of the study participants was using the known nephrotoxic drugs namely aminoglycosides, amphotericin B or cyclosporine.

Magnitude and associated factors of CIN: Table 2 summarizes the trends of serum creatinine from baseline and within 72 hours post procedure. At baseline, the mean serum creatinine of the total population was 105.4 ± 48.3 μmol/l. It slightly increased at 24 hours post-procedure (110.4 ± 57.7 μmol/l) and came back to pre-procedural levels at 72 hours (104.2 ± 54.1 μmol/l) post procedure. At 24 hours post procedure 10 (5%) patients had an absolute serum creatinine increase of ≥44 μmol/l while 24 (12.1%) patients’ serum creatinine increased by ≥25% from baseline. It is noted that all 10 patients with a ≥44 μmol/l absolute increase of serum creatinine from baseline met the ≥25% serum creatinine increase criteria, making the incidence of CIN at 24 hours post procedure to be 12.1% (Table 2).

The overall incidence of CIN, defined as absolute serum creatinine increase of ≥44 μmol/l from baseline and/or ≥25% increase of serum creatinine from baseline within 72 hours post angiography procedure was present in 40 (19.05%) patients. Of the 40 patients who developed CIN, 10 had CIN both at 24 hours and at 72 hours (Figure 1). Furthermore, 14 of the 24 patients with CIN at 24 hours had normal creatinine at 72 hours, while 16 out of the 26 patients with CIN at 72 hours had normal creatinine at 24 hours. None of the patients diagnosed to have CIN needed dialysis.

Table 3 compares the socio-demographic, clinical and peri-procedural characteristics between patients who developed CIN and those who did not. Patients with CIN did not differ from those without CIN in most of the socio-demographic and clinical characteristics. As seen in Table 3, age, gender, history of hypertension, mean blood pressure levels, proportion of diabetes, smoking or alcohol consumption did not significantly differ
between patients with CIN and in those without CIN, all $p>0.05$. Furthermore, mean eGFR as well as proportion with anemia did not differ between the two groups. However, patients with CIN were more likely to have a history of heart failure, previous myocardial infarction and were more likely to have received fluid therapy pre-procedural, with longer mean duration of the procedure as well as longer hospital stay post procedure (Table 3).

Factors found to be associated with CIN ($p<0.05$) and those with weak associations ($p≤0.25$) in univariate analysis (Table 3) were entered in logistic regression model to determine independent factors associated with the development of CIN. These factors were age ≥65, central obesity, history of heart failure, history of renal failure, taking angiotensin converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB), previous myocardial infarction, having pre-procedure IV fluids, procedure time >20 minutes, volume of contrast >100 ml, having 3-vessel disease on angiogram, and having >3 days post procedure hospital stay. Gender (female vs male) was then forced in the model as an important confounder. In the final logistic regression analysis (after removing interacting variables), the independent factors associated with development of CIN were history of heart failure (aOR=7.34, CI 1.55 - 34.83), central obesity (aOR=3.12, 95% CI 1.22 - 7.97), triple vessel disease on angiogram (aOR=10.14, 95% CI 2.07 - 49.65) and longer (≥3 days) post-procedure hospital stay (aOR=4.09, 1.75 - 9.76) irrespective of age and gender, all $p<0.05$ (Table 4).

Discussion

This study documents for the first time, that the incidence of CIN among unselected patients undergoing coronary angiography and percutaneous coronary intervention at the National Cardiac Referral Hospital in Tanzania is 19%. Furthermore, the development of CIN in this population is independently associated with pre-existing history of heart failure, presence of central obesity, multi-vessel disease and longer post-procedure hospital stay. The magnitude of CIN found in this study is lower than that reported by the study done in Nigeria among patients undergoing radiocontrast procedures (35.9%) [9]. The incidence found in our study is however, higher than reports from South Africa and Kenya [7,8]. Differences in the patients’ characteristics and procedures performed could explain some of the variations between ours and previous studies from the region. Our findings however, falls not far from the incidence reported in a review of literature by Gami et al. which reported an incidence of CIN ranging between 11 - 16% following coronary angiographic procedures in large studies in Europe and North America [5]. The finding that a pre-existing history of heart failure was independently associated with the development of CIN has been reported elsewhere in developed [16-18] as well as in developing countries [19,20]. Our study confirms this finding and adds to the sub-Saharan Africa literature that patients with heart failure are up to 7 times more at risk to develop CIN when compared to those without heart failure. The mechanism of CIN in heart failure has been described to be a result of poor pre-renal perfusion which results in a deleterious effect of renal vasoconstriction coupled with low preload that compromise the medullary oxygenation; and in the presence of contrast media this leads to increased nephrotoxicity and hence CIN [10].

Obesity, especially central obesity, is characterized by the presence of metabolic syndrome, itself a risk factor for renal impairment [21]. Previous studies have documented the association of obesity and/or metabolic syndrome and the development of CIN among patients undergoing any contrast administration [22] as well as those undergoing coronary angiography procedures [23,24]. However, others have dismissed this association as an independent risk factor [25]. The mediators of abnormal kidney function in obesity include physical compression of the kidneys by fat in and around the kidneys, activation of the renin angiotensin aldosterone...
system and increased sympathetic nervous system activation [26]. Of note, obesity was not included as a risk factor in the South African study [7] and in the Nigerian study obesity was not associated with CIN [9]. Our findings therefore need to be confirmed by other researchers in the region.

Patients with triple vessel disease are generally known to have accelerated or diffuse atherosclerosis which is linked to the development of CIN [18,27,28]. We found in this study that patients with triple vessel disease were 10-times more likely to get CIN when compared to those with lesser coronary artery disease. Apart from the deranged renal function, patients with triple vessel disease have impaired pumping ability of the heart which further impairs renal perfusion. Yet, another explanation is the fact that these patients require multistage angiography and/or interventions thus utilizing high volume of contrast media [29]. In fact, high volume of contrast medium was associated with CIN in univariate analysis in this study. Our finding therefore confirms similar observations from previous studies [16,30]. Although this study did not collect data on mortality, it is likely that patients with triple vessel disease and CIN will have worse long term outcomes similar to what was seen by Abe et al. in Japan, where triple vessel disease predicted CIN and was associated with increased longer term mortality after PCI [30].

We found patients who stayed longer in hospital (for three days or more) had at least 4 times higher likelihood to develop CIN irrespective of other variables. This observation agrees with the findings by previous researchers in Europe and North America [31,32]. However, the study from South Africa by Banda et al. which studied patients admitted due to any cause did not find this association, most likely due to the different patient population studied [7]. Longer hospital stay is an outcome of CIN and indicates the general poor condition of the patient. In the study by Marenzi et al. in Italy, development of CIN was strongly associated with longer hospital stay, complicated the clinical course and it was a predictor of increased mortality in that study population [32].

Our finding that patients who received fluids pre-procedure were more likely to develop CIN in univariate analysis deserves a special mention. This finding has been reported by others [7] and can be explained by preferential intravenous fluid administration in at risk patients as a preventive measure for CIN. Nevertheless, in tightly controlled studies as is the case for randomized control studies, hydration has proved to be a preventive measure to develop CIN [33,34]. In South Africa, the incidence of CIN was 15.8% and 26.3% in the pre-hydrated and non-hydrated patients, respectively [7].

In this study age, diabetes mellitus, pre-existing renal impairment as well as anemia were not associated with the development of CIN. This is in contrary to previous studies [7,9,16,18,35,36]. It is likely that our study population was not powered to detect these differences and only trends were observed in univariate analyses. These lack of associations have however, been as well observed in the few research on CIN in Africa. For example, age, diabetes and pre-existing renal failure were all not associated with CIN in the studies by Banda et al. in South Africa as well as in the study by Radwan et al. in Egypt [7,37]. Larger regional studies are therefore needed to look into the details of these observations. The strengths of this work include that this is the first study to report on the prevalence and risk factors of CIN in Tanzania. The prospective nature of the study gives a true picture of what happens to patients receiving contrast medium within 72 hours post cardiac angiographic procedures in our center. The study is limited since it is not possible to report on the long-term outcome of the patients with CIN as this was not part of the present study.

**Conclusion**

The incidence of CIN among patients undergoing coronary angiogram or percutaneous coronary intervention at the Jakaya Kikwete Cardiac
Institute is high (19%) and is independently associated with positive history of heart failure, central obesity, multi-vessel disease and longer post-procedure hospital stay.

What is known about this topic

- Use of contrast media for investigations as well as interventional procedures is increasing worldwide and in sub-Saharan Africa;
- Patients receiving contrast media are at risk to develop contrast induced nephropathy, which carries a risk to long-term renal damage and mortality.

What this study adds

- We document for the first time that CIN is present in 19% of patients undergoing coronary angiography and interventions at a cardiac referral hospital in Tanzania; this incidence is high but falls within the documented prevalence in sub-Saharan Africa of 9.9% to 35.9%, depending on the studied population;
- This study adds that, patients with pre-existing heart failure, obese and those with multiple coronary vessels disease carry higher risk to develop CIN.

Competing interests

The authors declare no competing interests.

Authors' contributions

Pilly Chillo is responsible for the research idea conception, data analysis and writing the manuscript; Ng’wigulu Malaja was involved in research idea conception, data collection, data analysis and manuscript writing; Peter Kisenge supervised the data collection and was involved in reviewing the manuscript. All the authors have read and agreed to the final manuscript.

Tables and figure

Table 1: socio-demographic, clinical and laboratory findings
Table 2: trends of serum creatinine from baseline to 24- and 72-hours post procedure
Table 3: socio-demographic, clinical and peri-procedural characteristics of patients with and without CIN
Table 4: independent factors associated with CIN among patients undergoing percutaneous coronary angiography and interventions at JKCI

Figure 1: venn diagram showing the distribution of 40 patients with CIN

References

1. Ozkan J. A snapshot of cardiology in Africa. Eur Heart. 2018;39(23): 2128-2129. PubMed | Google Scholar
2. Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK et al. Contrast induced nephropathy: updated ESUR contrast media safety committee guidelines. Eur Radiol. 2011;21(12): 2527-2541. PubMed | Google Scholar
3. Hou SH, Bushinsky DA, Wish JB, Cohen JJ, Harrington JT. Hospital-acquired renal insufficiency: a prospective study. Am J Med. 1983;74(2): 243-248. PubMed | Google Scholar
4. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis. 2002;39(5): 930-936. PubMed | Google Scholar
5. Gami AS, Garovic VD. Contrast nephropathy after coronary angiography. Mayo Clin Proc. 2004;79(2): 211-219. PubMed | Google Scholar
6. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006;(100): S11-15. PubMed | Google Scholar
7. Banda J, Duarte R, Dickens C, Dix-Peek T, Muteba M, Paget G et al. Risk factors and outcomes of contrast-induced nephropathy in hospitalized South Africans. S Afr Med J. 2016;106(7): 699-703. PubMed | Google Scholar
8. Kwasa EA, Vinayak S, Armstrong R. The role of inflammation in contrast-induced nephropathy. Br J Radiol. 2014;87(1041):20130738. PubMed | Google Scholar

9. Okoye O, Ojougwu L, Unuigbe E, Oviasu E. Frequency and risk factors of contrast-induced nephropathy after contrast procedures in a Nigerian tertiary centre. West Afr J Med. 2013;32(1):19-25. PubMed | Google Scholar

10. Toprak O, Citir M. Risk factors for contrast-induced nephropathy. Kidney Blood Press Res. 2006;29(2):84-93. PubMed | Google Scholar

11. McDonald RJ, McDonald JS, Bida JP, Carter RE, Fleming CJ, Misra S et al. Intravenous contrast material-induced nephropathy: causal or coincident phenomenon. Radiology. 2016;278(1):306. PubMed | Google Scholar

12. Hamid S, Groot W, Pavlova M. Trends in cardiovascular diseases and associated risks in sub-Saharan Africa: a review of the evidence for Ghana, Nigeria, South Africa, Sudan and Tanzania. Aging Male. 2019;22(3):169-176. PubMed | Google Scholar

13. World Health Organization. Waist circumference and waist-hip ratio: report of a WHO expert consultation, Geneva, 8 - 11 December 2008. 2011. Google Scholar

14. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247-254. PubMed | Google Scholar

15. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International Supplement. 2013;3:1-50.

16. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393-1399. PubMed | Google Scholar

17. Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36(5):1542-1548. PubMed | Google Scholar

18. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol. 2005;95(1):13-19. PubMed | Google Scholar

19. Bhatt S, Rajpal N, Rathi V, Avasthi R. Contrast induced nephropathy with intravenous iodinated contrast media in routine diagnostic imaging: an initial experience in a tertiary care hospital. Radiol Res Pract. 2016;2016:8792984. PubMed | Google Scholar

20. Kassem AM, Shazly SE. Study of contrast induced nephropathy in patients undergoing cardiac catheterization: upper Egypt experience. Value in Health. 2016;19(7):PA857. Google Scholar

21. Raikou VD, Gavriil S. Metabolic syndrome and chronic renal disease. Diseases. 2018;6(1):12. PubMed | Google Scholar

22. Hsieh TM, Tsai TH, Liu YW, Hsieh CH. Risk factors for contrast-induced nephropathy and their association with mortality in patients with blunt splenic injuries. Int J Surg. 2016 Nov;35:69-75. PubMed | Google Scholar

23. Alyavi AL, Alyavi BA, Uzokov JK, Payziev JJ, Ishakov SA, Azizov SI. Predictors of contrast induced nephropathy in patients with metabolic syndrome. European Heart Journal. 2017;38(suppl_1).

24. Ozcan OU, Adanir Er H, Gulec S, Ustun EE, Gerede DM, Goksuluk H et al. Impact of metabolic syndrome on development of contrast-induced nephropathy after elective percutaneous coronary intervention among nondiabetic patients. Clin Cardiol. 2015;38(3):150-156. PubMed | Google Scholar
25. Jaipaul N, Manalo R, Sadjadi SA, McMillan J. Obesity is not associated with contrast nephropathy. Ther Clin Risk Manag. 2010;6: 213-217. PubMed | Google Scholar

26. Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol. 2019;15(6): 367-385. PubMed | Google Scholar

27. Lopes NH, Paulitsch Fda S, Gois AF, Pereira AC, Stolf NA, Dallan LO et al. Impact of number of vessels disease on outcome of patients with stable coronary artery disease: 5-year follow-up of the medical, angioplasty and bypass surgery study (MASS). Eur J Cardiothorac Surg. 2008;33(3): 349-354. PubMed | Google Scholar

28. Weber-Mzell D, Kotanko P, Schumacher M, Klein W, Skrabal F. Coronary anatomy predicts presence or absence of renal artery stenosis: a prospective study in patients undergoing cardiac catheterization for suspected coronary artery disease. Eur Heart J. 2002;23(21): 1684-1691. PubMed | Google Scholar

29. Cigarroa RG, Lange RA, Williams RH, Hillis LD. Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. Am J Med. 1989;86(6 Pt 1): 649-652. PubMed | Google Scholar

30. Abe M, Morimoto T, Akao M, Furukawa Y, Nakagawa Y, Shizuta S et al. Relation of contrast-induced nephropathy to long-term mortality after percutaneous coronary intervention. Am J Cardiol. 2014;114(3): 362-368. PubMed | Google Scholar

31. Weisbord SD, Chen H, Stone RA, Kip KE, Fine MJ, Saul MI et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol. 2006;17(10): 2871-2877. PubMed | Google Scholar

32. Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 2004;44(9): 1780-1785. PubMed | Google Scholar

33. Solomon R, Werner C, Mann D, D’Elia J, Silva P. Effects of saline, mannitol and furosemide on acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331(21): 1416-1420. PubMed | Google Scholar

34. Taylor AJ, Hotchkiss D, Morse RW, McCabe J. PREPARED: preparation for angiography in renal dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. Chest. 1998;114(6): 1570-1574. PubMed | Google Scholar

35. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19): 2259-2264. PubMed | Google Scholar

36. McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: incidence, risk factors and relationship to mortality. Am J Med. 1997;103(5): 368-375. PubMed | Google Scholar

37. Radwan M, Fahmy AM, Nagieb M. Incidence of contrast induced nephropathy in patients with acute ST-segment elevation myocardial infarction treated with primary or rescue PCI. Al-Azhar Assiut Medical Journal. 2015;13(1): 1687-1693.
| Characteristic                          | Frequency | %  |
|----------------------------------------|-----------|----|
| **Gender**                             |           |    |
| Men                                    | 135       | 64.3|
| Women                                  | 75        | 35.7|
| **Age groups (years)**                 |           |    |
| 18 - 40                                | 8         | 3.8 |
| 41 - 65                                | 128       | 61.0|
| >65                                    | 74        | 35.2|
| **Cardiovascular risk factors**        |           |    |
| Known hypertensive                     | 182       | 86.7|
| Known diabetics                        | 75        | 37.7|
| Taking alcohol                         | 79        | 37.6|
| Cigarette smokers                      | 26        | 12.4|
| **Previous cardiovascular disease**    |           |    |
| History of heart failure               | 8         | 3.8 |
| History of renal failure               | 18        | 8.6 |
| Previous angiography procedure         | 42        | 22.6|
| **Medications used**                   |           |    |
| Diuretics                              | 113       | 53.8|
| ARBs                                   | 105       | 50.0|
| CCBs                                   | 46        | 21.9|
| ACEIs                                  | 29        | 13.8|
| NSAIDs                                 | 4         | 1.9 |
| Obese (BMI ≥30kg/m2)                   | 82        | 39.0|
| Central obesity                        | 119       | 56.7|
| **Hypertension stage**                 |           |    |
| Normal/controlled BP                   | 108       | 51.4|
| Stage 1                                | 71        | 33.8|
| Stage 2                                | 23        | 11.0|
| Stage 3                                | 8         | 3.8 |
| Anemia                                 | 60        | 28.6|
| High cholesterol                       | 68        | 33.5|
| Elevated FBG                           | 66        | 31.6|
| **Pre-procedure CKD stage**            |           |    |
| eGFR >60                               | 164       | 78.1|
| Stage 1                                | 38        | 18.1|
| Stage 2                                | 7         | 3.3 |
| Stage 3                                | 1         | 0.5 |

ARB: angiotensin converting enzyme inhibitor; CCB: calcium channel blocker; ACEI: angiotensin converting enzyme inhibitor; NSAID: non-steroidal anti-inflammatory drug; FBG: fasting blood glucose; BMI: body mass index; BP: blood pressure
Table 2: trends of serum creatinine from baseline to 24- and 72-hours post procedure

|                                | Baseline (N=210) | At 24 hours (N=199)* | At 72 hours (N=200)* |
|--------------------------------|------------------|-----------------------|-----------------------|
| Mean ± SD creatinine (μmol/l)  | 105.4 ± 48.3     | 110.4 ± 57.7          | 104.2 ± 54.1          |
| Mean ± SD eGFR (ml/min/1.73m2) | 78.8 ± 26.4      | 77.2 ± 27.3           | 81.8 ± 27.7           |
| Proportion with increased creatinine, n (%) | NA             | 105 (52.8)            | 98 (49.0)             |
| Proportion with decreased creatinine, n (%) | NA             | 92 (46.2)             | 102 (51.0)            |
| Proportion with un-changed creatinine, n (%) | NA             | 2 (1%)                | 0 (%)                 |
| Proportion with ≥44μmol/l, n (%)  | NA             | 10 (5%)               | 13 (6.5%)             |
| Proportion with 25% increase, n (%) | NA             | 24 (12.1%)            | 25 (12.5%)            |
| Proportion with CIN, n (%)       | NA             | 24 (12.1%)            | 26 (13.0%)            |

eGFR: estimated glomerular filtration rate; CIN: contrast induced nephropathy; *only 199 and 200 patients had creatinine measurements at 24 hours and 72 hours respectively; NA: not applicable
Table 3: socio-demographic, clinical and peri-procedural characteristics of patients with and without CIN

| Characteristic                        | CIN (n=40) | No CIN (n=170) | p-value |
|---------------------------------------|------------|----------------|---------|
| **Socio-demography**                  |            |                |         |
| Females, n (%)                        | 14 (35.0)  | 61 (35.9)      | 0.917   |
| Mean ± SD age (years)                 | 63.1 ± 11.6| 60.9 ±10.8     | 0.244   |
| Age ≥65 years, n (%)                  | 18 (45.0)  | 63 (37.1)      | 0.226   |
| **Clinical**                          |            |                |         |
| Hypertensive, n (%)                   | 35 (87.5)  | 147 (86.5)     | 0.863   |
| ≥Grade 2 hypertension, n (%)          | 5 (12.5)   | 26 (15.3)      | 0.654   |
| Overweight and obese, n (%)           | 33 (82.5)  | 133 (78.2)     | 0.551   |
| Central obese, n (%)                  | 27 (67.5)  | 92 (54.1)      | 0.124   |
| Diabetics, n (%)                      | 15 (37.5)  | 60 (35.3)      | 0.793   |
| Mean ± SD fasting blood sugar (mmol/l)| 7.2 ± 4.0  | 6.5 ± 2.9      | 0.221   |
| Anemic, n (%)                         | 14 (35.0)  | 46 (27.1)      | 0.314   |
| Elevated FBG, n (%)                   | 13 (32.5)  | 53 (31.4)      | 0.889   |
| Mean ± SD eGFR (mL/min/1.73 m2)       | 84.5 ± 32.3| 77.4 ± 24.8    | 0.128   |
| **CKD stages, n (%)**                 |            |                |         |
| eGFR > 60                             | 33 (82.5)  | 131 (77.1)     | 0.868   |
| Stage 3 CKD                           | 6 (15.0)   | 32 (18.8)      |         |
| Stage 4 CKD                           | 1 (2.5)    | 6 (3.5)        |         |
| Stage 5 CKD                           | 0 (0.0)    | 1 (0.6)        |         |
| Taking alcohol, n (%)                 | 15 (37.5)  | 64 (37.6)      | 0.986   |
| Smoking, n (%)                        | 6 (15)     | 20 (11.8)      | 0.576   |
| History of heart failure, n (%)       | 4 (10)     | 4 (2.4)        | 0.023   |
| History of renal failure, n (%)       | 4 (10)     | 14 (8.2)       | 0.120   |
| Taking NSAIDs, n (%)                  | 0 (0)      | 4 (2.4)        | 0.327   |
| Taking ACEIs or ARBs, n (%)           | 21 (52.5)  | 113 (66.5)     | 0.098   |
| Taking diuretics, n (%)               | 24 (60)    | 89 (52.4)      | 0.383   |
| **Peri-procedure**                    |            |                |         |
| Had myocardial infarction, n (%)      | 15 (37.5)  | 30 (17.6)      | 0.006   |
| Received angiography + PCI, n (%)     | 8 (20.0)   | 29 (17.1)      | 0.660   |
| Pre-procedural fluid given, n (%)     | 8 (20.0)   | 10 (5.9)       | 0.004   |
| Procedure duration ≥20min, n (%)      | 14 (35.0)  | 35 (20.6)      | 0.053   |
| Contrast volume ≥100ml, n (%)         | 10 (25.0)  | 20 (11.8)      | 0.031   |
| ≥3 vessel disease on CAG, n (%)       | 7 (17.5)   | 4 (2.4)        | <0.001  |
| ≥3 days post-procedure hospital stay, n (%) | 18 (45.0)  | 26 (15.3)      | <0.001  |

Results are mean ± SD unless stated otherwise; CIN: contrast induced nephropathy; NSAIDs: non-steroidal anti-inflammatory drugs; ACEIs: angiotensin converting enzyme inhibitors, ARBs: angiotensin receptor blockers; FBG: fasting blood glucose.
### Table 4: independent factors associated with CIN among patients undergoing percutaneous coronary angiography and interventions at JKCI

| Variable                                | cOR (95% CI) | p-value  | aOR (95% CI) | p-value  |
|-----------------------------------------|--------------|----------|--------------|----------|
| Age ≥65 (years)                         | 1.4 (0.69 - 2.78) | 0.354    | 1.41 (0.63 - 3.13) | 0.405    |
| Female gender                           | 0.96 (0.47 - 1.98) | 0.917    | 0.88 (0.38 - 2.01) | 0.756    |
| History of heart failure                | 4.6 (1.10 - 19.31) | 0.036    | 7.34 (1.55 - 34.83) | 0.012    |
| Central obesity                         | 1.8 (0.85 - 3.64) | 0.127    | 3.12 (1.22 - 7.97) | 0.017    |
| Given IV fluids pre-procedural          | 4.0 (1.47 - 10.92) | 0.007    | 2.43 (0.72 - 8.25) | 0.154    |
| Contrast volume ≥100 mls                | 2.5 (1.06 - 5.87) | 0.036    | 1.58 (0.55 - 4.47) | 0.396    |
| Three vessel disease on CAG             | 8.8 (2.44 - 31.79) | 0.001    | 10.14 (2.07 - 49.65) | 0.004    |
| ≥3 days hospital stay                   | 4.5 (2.14 - 9.59)  | <0.001   | 4.1 (1.75 - 9.76)  | 0.001    |

CIN: contrast induced nephropathy; CAG: coronary angiography

**Figure 1:** venn diagram showing the distribution of 40 patients with CIN